Brooks Center for Rehabilitation Studies in Collaboration with the University of Florida
Looking for studies or trials in a specific area?

Brooks Teams with Mayo Clinic for Intracerebral Hemorrhage (ICH) Study

Home > - Research > -Innovations > 995

Executive Summary:

As our population ages, the number of Intracerebral Hemorrhage (ICH), is increasing rapidly. Yet, ICH is the least studied category of stroke with regard to cognitive and emotional outcomes. In November 2006, Brooks Rehabilitation gave a $500,000 donation to Mayo Clinic Jacksonville in order to conduct a research trial to study the best treatment options for strokes resulting from ICH.  With a 40% fatality rate in population-based studies, it is the most devastating type of stroke. ICH also occurs frequently when the drug Warfarin-an anticoagulation drug-is administered for blood thinning to prevent clots. Individuals who survive ICH may have significant cognitive, motor and sensory deficits at the time of hospital discharge.

The purpose of this study is to establish the natural history of cognitive recovery in survivors of spontaneous and Warfarin associated Intracerebral Hemorrhage (strokes caused by bleeding) and to compare and contrast this recovery to that observed in ischemic type strokes (those caused by clotting).

To accomplish this goal, a team of researchers from Mayo Clinic and Brooks Rehabilitation will be collecting data from patients admitted to Brooks Rehabilitation for Inpatient Stroke Rehabilitation as well as other stroke patients in the community. The project goals are to collect and compare the performance on standardized cognitive and emotional tests among the following groups:

 30 individuals diagnosed with ICH stroke
 30 individuals with ischemic type stroke
 30 non-stroke individuals of similar age ranges

Consenting participants, including stroke patients and their caregivers, will be enrolled during their acute or rehab hospitalization. The actual assessments will occur 15 and 90 days post stroke onset. The tools that will be developed as a result of studying the data from these assessments will allow the researchers to design rigorous, post-acute interventional trials. The long-term objectives are to develop and test treatments-both behavioral and pharmacologic-for survivors of ICH as well as to discover predictors of treatment response, such as genetics and co-morbidities. Data collection began in May, 2007.

CO-PRINCIPAL INVESTIGATORS 
Beth K Rush, Ph.D., neuropsychologist and Assistant professor in the Department of Psychiatry and    Psychology at Mayo Clinic
Thomas G. Brott, M.D., professor of Neurology, specializing in cerebrovascular disease, and Director for research at Mayo Clinic
Trevor Paris, M.D., Medical Director Brooks Stroke Center of Excellence

CO-INVESTIGATORS
Shirley Koehler, Ph.D., neuropsychologist for Brooks Rehabilitation Hospital
Kerry Maher, M.D., medical director of admissions for Brooks Rehabilitation Hospital
Russell Addeo, Ph.D., neuropsychologist for Brooks Rehabilitation Hospital
Floris Singletary, M.S., clinical coordinator for the Brooks Center
Deborah Stewart, M.D., physiatrist and Chief Medical Director at Brooks Rehabilitation